This ‘Strong Buy’ Penny Stock Just More Than Quadrupled on Clinical Trial Results. Should You Buy It Here?

Capricorn Therapeutics (CAPR) shares more than quadrupled on Dec. 3 after the biotech company announced late-stage HOPE-3 clinical trial results for deramiocel, its investigational treatment for Duchenne Muscular Dystrophy. The positive results prompted notable short-seller Martin Shkreli to publicly acknowledge his “bad call” on CAPR, reversing his earlier prediction that the HOPE-3 trial would fail. More News from Barchart His admission underscores the binary nature of biotech investments, where succe ...